News | Lung Cancer | March 13, 2017

FDG PET/CT Found Useful in Certain Lung Cancer Patients

New evidence discussed in AJR study on treatment response, follow-up and surveillance of lung cancer

FDG PET/CT, lung cancer, radiation therapy, AJR study, American Journal of Roentgenology

March 13, 2017 — FDG positron emission tomography/computed tomography (PET/CT) is a valuable imaging tool for treatment assessment of patients with lung cancer, though systematic evidence for its comparative effectiveness with conventional imaging, such as chest CT, is still evolving, according to a new study.

Authors of the study titled "The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer" published their findings in the February 2017 issue of the American Journal of Roentgenology.

In this review, the authors summarized the existing evidence in the literature concerning use of PET/CT for both assessing the efficacy of treatment response and performing post-treatment follow-up of lung cancer.

"FDG PET/CT is most useful when there is clinical suspicion or other evidence for disease recurrence or metastases," said study coauthor Rathan M. Subramaniam, of the department of radiology, University of Texas Southwestern Medical Center, Dallas. "Using FDG PET/CT for routine surveillance without any clinical suspicion should be discouraged until its value for patient survival outcomes is fully established."

The National Comprehensive Cancer Network (NCCN) recommends the use of FDG PET/CT for appropriately staging lung cancer and avoiding futile thoracotomies. It also recommends the imaging for accurate radiation therapy (RT) planning for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). However, NCCN does not recommend routine use of FDG PET/CT for treatment response evaluation and follow-up in lung cancer.

According to the study authors, FDG PET/CT is usually recommended 12 weeks after completion of concurrent chemoradiation therapy to minimize radiation-related inflammatory uptake leading to false-positive studies. In some cases, radiation-related therapy changes, especially with stereotactic body radiotherapy, can last for many months. In these circumstances, a follow-up FDG PET/CT in three months is suggested to ensure resolution of therapy-related FDG uptake. FDG PET/CT can be performed four weeks after completion of chemotherapy or surgery (without concurrent radiation), because the therapy-related inflammatory uptake is less and subsides within a shorter time.

The sequencing, cost analysis and comparative effectiveness of FDG PET/CT and conventional imaging modalities in the follow-up setting need to be investigated.

Lung cancer remains the leading cause of cancer-related mortality worldwide, accounting for about 1.6 million deaths yearly. Despite significant advances in both diagnostic and therapeutic approaches, the overall five-year survival rate for lung cancer is 17.4 percent. However, this is largely dependent on the stage of diagnosis, with a survival rate of 54.8 percent for localized and 4.2 percent for disease that has metastasized in other parts of the body.

Lung cancer has historically been divided into two main types: NSCLC (85 percent of cases) and SCLC (10-15 percent of cases). A multidisciplinary approach including the use of advanced imaging techniques for early accurate staging of disease and delivery of treatment is needed to avoid futile treatments and improve overall survival, which, in turn, influence the patient's quality of life.

Surgery is usually the primary treatment modality for localized disease in patients with lung cancer. Even after curative surgery, patients remain at risk for the development of recurrence or a secondary pulmonary malignancy. Post-treatment follow-up usually consists of a combination of physical examination, laboratory tests and imaging. No single modality is simultaneously sensitive, specific and cost-effective; thus, a combined approach is needed for the detection of tumor recurrence.

PET is a noninvasive imaging modality that is promising in the evaluation of lung cancer and is currently used clinically for initial antitumor treatment strategy (for staging, treatment planning, and delivery of radiation treatment) and for subsequent antitumor treatment strategy (treatment response assessment and detection of recurrence in follow-up).

For more information: www.ajronline.org

Related Content

Norwegian Study Confirms Benefits of Pressure-Based Breast Compression for Mammography
News | Mammography | May 22, 2017
Sigmascreening recently announced that a large independent Norwegian study further confirms Sigma’s hypothesis that...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
ASTRO's 59th Annual Meeting Will Explore Art and Science of Radiation Oncology
News | Radiation Therapy | May 19, 2017
Registration has opened for the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO), which will...
MidMichigan Medical Center to Install RAD Technology Temporary Radiotherapy Vault
News | Radiation Therapy | May 17, 2017
May 17, 2017 — RAD Technology Medical Systems and MidMichigan Medical Center — Alpena broke ground the end of March o
ACR Select Extended to Cover Pediatric Imaging Indications and Exams
News | Clinical Decision Support | May 17, 2017
May 17, 2017 — Through the support of the American College of Radiology and the contribution of leading experts from
News | Radiation Therapy | May 16, 2017
Proton International announced the successful financing of a new state-of-the-art radiation therapy center and a...
Seno Medical's Imagio Opto-Acoustic Breast Imaging System Proves Strong Predictor of Malignancy
News | Breast Imaging | May 16, 2017
Seno Medical Instruments Inc. recently announced that is Imagio opto-acoustic (OA/US) breast imaging system results...
Study Indicates Q-Collar May Help Protect Football Players' Brain Function
News | Neuro Imaging | May 15, 2017
A new study of high school football players adds to mounting evidence that the Q-Collar may help reduce brain injury...
FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017
Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be stopped in the...
Proton Monte Carlo Dose Calculation Now Part of RayStation Treatment Planning
News | Treatment Planning | May 15, 2017
RaySearch demonstrated a new Monte Carlo dose planning feature for proton therapy on its RayStation system at the 2017...
Overlay Init